SVIMS to offer AI-based medical services to needy soon: TTD chairman
Tirupati: Sri Venkateswara institute of medical sciences (SVIMS), a multi-specialty hospital established by the Tirupati trust, will soon offer Artificial Intelligence-based medical services and perform a higher share of surgeries through robotic arms, Tirumala Tirupati Devasthanams (
TTD
) chairman BR Naidu announced.
Taking part as chief guest at the 13th Convocation of the TTD-run medical university held in Tirupati on Wednesday, Naidu recalled the institute's meteoric rise right from its conception by the then chief minister Late NT Rama Rao in 1993 to getting on the verge of becoming an Institute of National Importance (INI).
The institute has been reaching out to the poor and needy patients of the backward Rayalaseema region for the last three decades, offering services to 1500 out patients and 750 in patients everyday.
The college produces 175 female doctors every year in the super specialties of cardiology, cardiac surgery, neurology, neurosurgery, nephrology, urology and oncology.
"SVIMS is only the second in the public sector in the entire country to run an all-women medical college, which is a matter of pride", TTD chief added.
TTD EO J Shyamala Rao congratulated the 501 young doctors graduating from the institute and hailed SVIMS for becoming the first public sector medical institute in India to perform triple transplantation surgery of heart, liver and kidney.
SVIMS Director and vice-chancellor Dr RV Kumar read out the annual report and thanked the TTD trust board for taking up developmental works at the hospital.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Pig tissue cornea implants offers new treatment for advanced keratoconus
Hyderabad: According to a recent study conducted by doctors at L V Prasad Eye Institute (LVPEI) in Hyderabad, cornea implants made from pig tissues might offer a new treatment option for patients with advanced keratoconus. Keratoconus causes the cornea to become too thin and bulge, resulting in blurred vision and, in severe cases, significant vision impairment. The study, published in the US-based Journal of Refractive Surgery, aimed to determine the efficacy of xenogeneic corneal implants, whereby damaged or diseased corneal tissue is replaced with tissue from a different species, typically pigs. Doctors said this reduces the need for human corneas, which are already hard to find in many places. During the clinical trial, doctors placed a small, soft, disc-shaped piece of tissue called a lenticule, made from porcine (pig) collagen, into the corneas of nine patients with advanced keratoconus. The average age of the patients was 28 years. Following the procedure, all of the patients' vision improved significantly as none of their bodies rejected the implants. Their logMAR improved from 1.43 to 0.78. However, in two cases, the tissue around the implant started to thin again and further treatment was required. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Heads Turn as Walgreens Shoppers Discover 87¢ ED Pills fridayplans Learn More Undo Distance vision improved "All the patients have been followed up regularly and are doing well,'"said Dr Rashmi Deshmukh, the study's lead author from LVPEI, told TOI, adding that as well as improving distance vision without glasses, the results showed that the bulging part of the eye became flatter over time. Doctors said that the implants are effective because they resemble human corneas. "Among the species that have been explored so far, porcine collagen most closely resembles human collagen, which is why it is the preferred choice. However, it may be possible in the future for corneal implants to be made from collagen of other species too," said Dr Rashmi. The doctors said that the study was necessary because usual cases of keratoconus could be treated with minimal surgery, after which contact lenses or glasses could be used to improve visual acuity. However, these treatments could only be used if the cornea was sufficiently thick. There were, however, limited treatments available for cases where keratoconus advanced and the cornea became too thin. Only corneal transplantation (keratoplasty), another surgical procedure, was possible. Although pig implants have provided a breakthrough, doctors still need to examine the 'crosslinking process' to determine whether any of the chemicals involved cause an inflammatory reaction in the eye. "Further research is needed to see if there is any way to modify the pig implant to allow important nutrients to reach the front part of the cornea (the part above the implant) to maintain healthy eyes," said Dr Rashmi. Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .
Time of India
2 hours ago
- Time of India
Bharat Biotech in-licences GSK's Shigella vaccine
Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development Shigella vaccine candidate, altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, a severe form of bacterial diarrhoea that largely affects children aged below five years in low- and middle-income countries. While GSK has already conducted Phase I and II trials in Europe and Africa, Bharat Biotech will take up further development with Phase III clinical trials, regulatory advancement, and large-scale manufacturing, the Hyderabad-based vaccine maker said on Thursday. As part of the agreement, GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalised modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. "The in-licensed candidate, altSonflex1-2-3, already showed encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response," Bharat Biotech said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Toulouse: Nous recherchons des personnes pour tester les nouvelles aides auditives HearPro En savoir plus Undo "Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals," it added. Bharat Biotech Executive Chairman Dr Krishna Ella said: "With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment." He pointed out that Bharat Biotech already has a significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. In 2021, GSK had inked a product transfer agreement for the world's first malaria vaccine, RTS,S, with Bharat Biotech. Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .
Time of India
7 hours ago
- Time of India
Bharat Biotech in-licences GSK's Shigella vaccine candidate
HYDERABAD: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licenced pharma giant GSK's Shigella vaccine candidate -- altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, which is a severe form of bacterial diarrhoea that largely affects children aged five years and below in low- and middle-income countries. While GSK has already conducted Phase-I and II trials in Europe and Africa, Bharat Biotech will be taking up further development with Phase-III clinical trials, regulatory advancement and large-scale manufacturing, Bharat Biotech said on Thursday. As part of the agreement, GSK will continue its support to the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalized modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. 'The in-licensed candidate, altSonflex1-2-3, has already shown encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response,' the Hyderabad-based vaccine maker said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it better to shower in the morning or at night? Here's what a microbiologist says CNA Read More Undo 'Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals,' it added. Bharat Biotech executive chairman Dr Krishna Ella said: 'With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment.' He pointed out that the addition of this vaccine candidate to its portfolio will strengthen Bharat Biotech's already significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. GSK already has an established relationship with BBIL, after it signed a product transfer agreement for the world's first malaria vaccine, RTS,S, to the Hyderabad-based company in 2021. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
